Key Highlights
- Presidential executive order issued Saturday mandates expedited FDA evaluation of psychedelic medications for mental health treatment
- AtaiBeckley stock surged 28% before market open; Compass Pathways climbed 26%
- Commissioner’s National Priority Vouchers will reduce review periods from 6–10 months down to 1–2 months for breakthrough-designated therapies
- Ibogaine, currently a Schedule I controlled substance under investigation for opioid dependency, receives special emphasis in the directive
- Federal commitment of $50 million earmarked for ibogaine research initiatives
President Trump issued an executive directive Saturday mandating accelerated FDA review processes for psychedelic pharmaceutical compounds. The presidential order carries the title “Accelerating Medical Treatments for Serious Mental Illness.”
The mandate encompasses therapeutic interventions for treatment-resistant depression, post-traumatic stress disorder, and substance use disorders.
FDA Commissioner Marty Makary indicated regulatory determinations for certain compounds may arrive by summer.
The directive compresses standard evaluation timelines from 6–10 months to just 1–2 months for pharmaceuticals already designated as “breakthrough therapies.” This acceleration mechanism operates via Commissioner’s National Priority Vouchers.
Psychedelic pharmaceutical company shares experienced dramatic gains in Monday premarket activity. AtaiBeckley soared 28%, Compass Pathways advanced 26%, GH Research gained 19%, Definium Therapeutics climbed 15%, Cybin rose approximately 15%, and Enveric BioSciences increased 7%.
AtaiBeckley commands approximately $1.5 billion in market capitalization, positioning it among the sector’s largest publicly traded entities.
Biotechnology Firms Experience Sharp Rally Following Presidential Action
The company’s primary candidate, BPL-003, represents an intranasal formulation designed for treatment-resistant depression. Phase 3 clinical trials are scheduled to commence within the current quarter.
Compass Pathways, headquartered in Britain, is advancing COMP360, a synthetically produced psilocybin compound. The therapy is undergoing late-phase clinical investigation for treatment-resistant depression and has secured FDA Breakthrough Therapy status.
The presidential directive explicitly references ibogaine, a psychoactive alkaloid extracted from African plant species. This compound maintains Schedule I classification under U.S. federal regulations, designating it as lacking recognized therapeutic applications.
Ibogaine shows promise as an intervention for opioid dependency. The order directs regulatory authorities to facilitate access through the Right to Try Act, legislation Trump enacted in 2018.
Cardiac toxicity associated with ibogaine remains thoroughly documented, presenting ongoing regulatory concerns.
Federal Investment and Market Expert Commentary
Trump announced $50 million in federal funding dedicated to ibogaine research programs.
Jefferies analyst Andrew Tsai characterized the directive as an “official stamp of validation to the class,” confirming genuine governmental backing.
RBC analyst Brian Abrahams described the signing as “a substantial step towards diminishing regulatory risk” surrounding psychedelic pharmaceuticals.
Health Secretary Robert F. Kennedy Jr. has advocated publicly for ibogaine as an alternative intervention for depression and related psychiatric conditions.
Bipartisan congressional representatives have announced intentions to advance legislation broadening psychedelic therapy accessibility.
FDA Commissioner Makary verified the agency’s readiness to implement expedited procedures under the new presidential mandate.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
